Jack A Khattar's Insider Trades & SAST Disclosures
Jack A Khattar's most recent trade in Supernus Pharmaceuticals Inc was a trade of 16,850 Common Stock done . Disclosure was reported to the exchange on April 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jack A Khattar.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Other type of transaction at price $ 0.00 per share. | 02 Apr 2025 | 16,850 | 1,008,683 (1%) | 0% | - | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Other type of transaction at price $ 0.00 per share. | 02 Apr 2025 | 16,850 | 1,005,600 (1%) | 0% | - | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 35,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 35,000 | 1,008,638 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.06 per share. | 10 Mar 2025 | 16,805 | 991,833 (1%) | 0% | 32.1 | 538,768 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 38,640 | 0 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 38,640 | 992,219 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.11 per share. | 07 Mar 2025 | 18,581 | 973,638 (1%) | 0% | 39.1 | 726,703 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 35,000 | 35,000 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 331,660 | 331,660 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2025 | 38,640 | 38,640 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 38,640 | 964,812 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Khattar Jack A. | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 38,640 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Khattar A. Jack | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.59 per share. | 27 Dec 2024 | 18,567 | 946,245 (1%) | 0% | 35.6 | 660,800 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 14,000 | 960,245 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Khattar Jack A. | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 14,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.59 per share. | 27 Dec 2024 | 6,666 | 953,579 (1%) | 0% | 35.6 | 237,243 | Common Stock |
| Supernus Pharmaceuticals Inc | A. Jack Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 38,640 | 38,640 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 14,000 | 14,000 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.13 per share. | 08 Nov 2024 | 125,000 | 1,051,172 (2%) | 0% | 9.1 | 1,141,250 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 36.29 per share. | 08 Nov 2024 | 125,000 | 926,172 (1%) | 0% | 36.3 | 4,536,250 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 125,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 36.68 per share. | 07 Nov 2024 | 125,000 | 926,172 (1%) | 0% | 36.7 | 4,585,000 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 125,000 | 125,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.13 per share. | 07 Nov 2024 | 125,000 | 1,051,172 (2%) | 0% | 9.1 | 1,141,250 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 21,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 21,000 | 936,217 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.90 per share. | 03 Sep 2024 | 10,045 | 926,172 (1%) | 0% | 34.9 | 350,571 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2024 | 21,000 | 21,000 | - | - | Performance Share Unit | |
| scPharmaceuticals Inc | Jack A. Khattar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 19,750 | 19,750 | - | - | Stock Option (Right to Buy) | |
| Cognition Therapeutics Inc | Jack A. Khattar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 8,500 | 14,500 | - | 0 | Common Stock | |
| Cognition Therapeutics Inc | Jack A. Khattar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 8,500 | 8,500 | - | - | Stock Option (right to buy) | |
| Supernus Pharmaceuticals Inc | Khattar Jack A. | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 35,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | A. Jack Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 35,000 | 932,005 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.94 per share. | 28 Feb 2024 | 16,788 | 915,217 (1%) | 0% | 27.9 | 469,057 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack Khattar A. | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 322,000 | 322,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | A. Khattar Jack | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 35,000 | 35,000 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | A. Khattar Jack | Director, President, CEO | Other type of transaction at price $ 0.00 per share. | 12 Feb 2024 | 16,500 | 897,005 (1%) | 0% | - | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Other type of transaction at price $ 0.00 per share. | 12 Feb 2024 | 16,500 | 1,022,450 (1%) | 0% | - | Common Stock | |
| Supernus Pharmaceuticals Inc | A. Jack Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2023 | 25,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | A. Khattar Jack | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2023 | 25,000 | 892,463 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | A. Khattar Jack | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.66 per share. | 22 Dec 2023 | 11,958 | 880,505 (1%) | 0% | 27.7 | 330,758 | Common Stock |
| Supernus Pharmaceuticals Inc | Khattar A. Jack | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 25,000 | 25,000 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 35,000 | 35,000 | - | - | Performance Share Unit | |
| Cognition Therapeutics Inc | Jack A. Khattar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 6,000 | 6,000 | - | 0 | Common Stock | |
| Cognition Therapeutics Inc | Jack A. Khattar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| scPharmaceuticals Inc | Jack A. Khattar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,300 | 17,300 | - | - | Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 31,250 | 864,272 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 31,250 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.47 per share. | 11 May 2023 | 15,005 | 849,267 (1%) | 0% | 36.5 | 547,232 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 31,250 | 31,250 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 20,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 20,000 | 833,022 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 280,000 | 280,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 20,000 | 20,000 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Other type of transaction at price $ 0.00 per share. | 15 Feb 2023 | 8,750 | 1,038,950 (1%) | 0% | - | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Other type of transaction at price $ 0.00 per share. | 15 Feb 2023 | 8,750 | 813,022 (1%) | 0% | - | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 02 Feb 2023 | 22,515 | 817,674 (1%) | 0% | 9.6 | 215,243 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 22,515 | 25,367 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 42.05 per share. | 02 Feb 2023 | 13,532 | 804,142 (1%) | 0% | 42.1 | 569,088 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 330 | 25,037 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 02 Feb 2023 | 330 | 804,472 (1%) | 0% | 9.6 | 3,155 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 42.02 per share. | 02 Feb 2023 | 200 | 804,272 (1%) | 0% | 42.0 | 8,404 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 498 | 47,882 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 01 Feb 2023 | 498 | 795,459 (1%) | 0% | 9.6 | 4,761 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 42.01 per share. | 01 Feb 2023 | 300 | 795,159 (1%) | 0% | 42.0 | 12,602 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 1,620 | 48,380 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 31 Jan 2023 | 1,620 | 795,937 (1%) | 0% | 9.6 | 15,487 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 42.01 per share. | 31 Jan 2023 | 976 | 794,961 (1%) | 0% | 42.0 | 41,002 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 18 Jan 2023 | 8,080 | 799,253 (1%) | 0% | 9.6 | 77,245 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2023 | 8,080 | 50,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 40.40 per share. | 18 Jan 2023 | 4,936 | 794,317 (1%) | 0% | 40.4 | 199,394 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 17 Jan 2023 | 41,920 | 816,619 (1%) | 0% | 9.6 | 400,755 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 41,920 | 58,080 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 40.03 per share. | 17 Jan 2023 | 25,446 | 791,173 (1%) | 0% | 40.0 | 1,018,728 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 20 Dec 2022 | 18,472 | 826,053 (1%) | 0% | 9.6 | 176,592 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2022 | 18,472 | 100,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2022 | 15,625 | 807,581 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 38.14 per share. | 20 Dec 2022 | 11,354 | 814,699 (1%) | 0% | 38.1 | 433,070 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 20 Dec 2022 | 6,528 | 795,962 (1%) | 0% | 9.6 | 62,408 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2022 | 6,528 | 118,472 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 38.02 per share. | 20 Dec 2022 | 4,006 | 791,956 (1%) | 0% | 38.0 | 152,317 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2022 | 17,794 | 125,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 23 Nov 2022 | 17,794 | 800,569 (1%) | 0% | 9.6 | 170,111 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 35.18 per share. | 23 Nov 2022 | 11,135 | 789,434 (1%) | 0% | 35.2 | 391,685 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2022 | 3,616 | 142,794 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 23 Nov 2022 | 3,616 | 785,034 (1%) | 0% | 9.6 | 34,569 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 35.05 per share. | 23 Nov 2022 | 2,259 | 782,775 (1%) | 0% | 35.1 | 79,189 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2022 | 959 | 146,410 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 22 Nov 2022 | 959 | 782,018 (1%) | 0% | 9.6 | 9,168 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 22 Nov 2022 | 600 | 781,418 (1%) | 0% | 35.0 | 21,001 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2022 | 848 | 147,369 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 21 Nov 2022 | 848 | 781,590 (1%) | 0% | 9.6 | 8,107 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 35.01 per share. | 21 Nov 2022 | 531 | 781,059 (1%) | 0% | 35.0 | 18,592 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.56 per share. | 15 Nov 2022 | 1,783 | 781,857 (1%) | 0% | 9.6 | 17,045 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2022 | 1,783 | 148,217 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 15 Nov 2022 | 1,115 | 780,742 (1%) | 0% | 35.0 | 39,028 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2022 | 5,895 | 0 | - | - | Stock Appreciation Right | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2022 | 5,895 | 781,454 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.75 per share. | 14 Sep 2022 | 1,380 | 780,074 (1%) | 0% | 33.8 | 46,575 | Common Stock |
| Supernus Pharmaceuticals Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 39,530 | 5,895 | - | - | Stock Appreciation Right |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges